Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- GSK Receives Complete Response Letter for "Undisclosed" Yucky Drug
- GlaxoSmithKline and drug development partner Eurand have received a "complete response letter" from the FDA for a mystery compound -- EUR-1048. GSK and Eurand have both declined to reveal what EUR-1048 is for. Eurand's statement says: EUR-1048 is an orally disintegrating tablet ODT formulation with an...
- Blog posts 2008-12-28
Additional Resources
- Eurand Prices Its Initial Public Offering.
- MILAN, Italy and DAYTON, Ohio, May 17 /PRNewswire/ -- - Eurand to list shares on Nasdaq Global Market under the symbol "EURX" Eurand, a global specialty pharmaceutical company, announced today the pricing of its initial public offering of 7 million Ordinary Shares...
- Research articles 2007-05-17
- Eurand to Present at Pacific Growth Equities 2005 Life Sciences Growth Conference.
- MILAN, Italy, June 6 /PRNewswire/ -- Eurand announced today that Gearoid Faherty, Chairman and CEO, will present an overview of the company at the 2005 Life Sciences Growth Conference sponsored by Pacific Growth Equities on Tuesday, June 7, 2005. The presentation will be...
- Research articles 2005-06-06
- FDA Approval Confirms Eurand's Long-Term Growth Potential
- VFC submits: A comment from Kenneth regarding Eurand EURX: Thanks so much for taking the time to reply our many queries. I was wondering if you see any upside potential in Eurand EURX. The company recently received FDA approval for Zenpep, the only FDA-approved pancreatic...
- External links 2009-09-15
- Zacks Analyst Blog Highlights: U.S. Cellular, Telephone and Data Systems, Eurand NV and Cephalon
- CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: U.S. Cellular (NYSE: USM), Telephone and Data Systems (NYSE: TDI), Eurand...
- Research articles 2008-01-14
- Zacks Analyst Blog Highlights: Eurand NV, Cephalon and GlaxoSmithKline
- CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eurand NV (Nasdaq: EURX), Cephalon, Inc. (Nasdaq: CEPH) and GlaxoSmithKline (NYSE:...
- Research articles 2008-03-11
- Zacks Analyst Interview Highlights: Regeneron Pharmaceuticals, ZymoGenetics, Eurand N.V., Myriad Genetics and BioMarin Pharmaceuticals
- CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Regeneron Pharmaceuticals (Nasdaq: REGN), ZymoGenetics Inc. (Nasdaq: ZGEN), Eurand N.V. (Nasdaq: EURX), Myriad Genetics (Nasdaq: MYGN) and BioMarin Pharmaceuticals (Nasdaq: BMRN).
- Research articles 2008-04-22
- Zacks Analyst Blog Highlights: Eurand NV, Cephalon, GlaxoSmithKline, Kodiak Oil & Gas and Devon Energy
- CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eurand NV (Nasdaq: EURX), Cephalon (Nasdaq: CEPH), GlaxoSmithKline (NYSE: GSK), Kodiak...
- Research articles 2008-05-19
- Zacks Analyst Interview Highlights: Onyx Pharmaceuticals, ZymoGenetics, Eurand N.V., Myriad Genetics and BioMarin
- CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Onyx Pharmaceuticals (Nasdaq: ONXX), ZymoGenetics Inc. (Nasdaq: ZGEN), Eurand N.V. (Nasdaq: EURX), Myriad Genetics (Nasdaq: MYGN) and BioMarin Pharmaceuticals, Inc. (Nasdaq: BMRN). A synopsis of today's Analyst Interview is presented below....
- Research articles 2008-01-25
- Expecting FDA Approval for Eurand's Zenpep
- Eurand Inc. EURX is waiting for the FDA to decide upon its proprietary pancreatic enzyme product Zenpep for exocrine pancreatic insufficiency. The condition is associated with various diseases, including chronic pancreatitis, cystic fibrosis, pancreatic cancer, partial or total gastrectomy, pancreatic resection and other causes. The various causes of exocrine pancreatic...
- External links 2009-06-24
- Eurand N.V. Q2 2009 Earnings Call Transcript
- Eurand N.V. EURX Q2 2009 Earnings Call Transcript August 6, 2009 8:30 am ET
- External links 2009-08-06
- Eurand Files IPO Registration Statement with SEC.
- MILAN, Italy and DAYTON, Ohio, May 1 /PRNewswire/ -- MILAN, Italy and DAYTON, Ohio, May 1 /PRNewswire/ --
- Research articles 2007-05-01
- Cephalon, Inc. to Acquire Amrix(R) - a Eurand Diffucaps(R) Product.
- MILAN, Italy and DAYTON, Ohio, August 23 /PRNewswire/ -- MILAN, Italy and DAYTON, Ohio, August 23 /PRNewswire/ --
- Research articles 2007-08-23
- Eurand Added to NASDAQ Biotechnology Index.
- AMSTERDAM, Netherlands, November 12 /PRNewswire/ -- AMSTERDAM, Netherlands, November 12 /PRNewswire/ --
- Research articles 2007-11-12
- Eurand Announces License Agreement with GlaxoSmithKline.
- MILAN, Italy, and VANDALIA, Ohio, October 4 /PRNewswire/ -- MILAN, Italy, and VANDALIA, Ohio, October 4 /PRNewswire/ --
- Research articles 2006-10-04
- Eurand N.V. Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you, sir Operator Instructions. Our first question is from the line of Rich Silver with Barclays Capital. Please go ahead with your question. Rich Silver - Barclays Capital Mario? Mario Crovetto Hi, Rich. Rich Silver - Barclays Capital Hey, how are you? I’m wondering if you...
- Earnings calls 2009-03-05
- Eurand N.V. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. We will now be conducting a question-and-answer session. Operator Instructions Our first question is coming from Rich Silver from Barclays Capital. Rich Silver - Barclays Capital Good morning. Gearoid Faherty Hi, Rich. Rich Silver - Barclays Capital Can you just talk about SG&A; you...
- Earnings calls 2009-05-07
- Eurand N.V. Q2 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator instructions Our first question is coming from John Newman with Oppenheimer & Company. Please state your question. John Newman – Oppenheimer & Company Hi, guys. Thanks for taking the question. Actually I had a couple – I'll just ask two for now. Do you...
- Earnings calls 2009-08-06
- Eurand N.V. Q3 2009 Earnings Conference Call
- Question-and-Answer SessionOperator Thank you, sir. Ladies and gentlemen at this time we will be conducting a question-and-answer session. Operator Instructions. One moment please while we pull for questions. Ladies and gentlemen our first question comes from the line of Annabel Samimy with Thomas Weisel. Please proceed with your question....
- Earnings calls 2009-11-05
- << Previous
- page 1 of 1
- Next >>
